TCTR20240427014尚未招募1 期
A Bioequivalence study of a multiple dose (steady state) randomized, open-label, two-way crossover design with two-period, two-treatment and two-sequence between Venlafaxine Prolonged -release Capsules BP 150 mg in healthy Thai volunteers under fed condition
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •1. Willingness to provide written informed consent prior to participate in the study. 2. Healthy Thai subjects are between 18 to 55 years of age. 3. The Body Mass Index (BMI) ranges from 18.5 to 30 kg/m2. 4. Comprehensive of the nature and purpose of the study and compliance with the requirement of the entire protocol and allow investigators to draw 7 mL of blood for monitoring subjects safety after the completion of the study. 5. Negative urine pregnancy test for women and no breast-feeding. 6. Absence of significant diseases or clinically significant abnormal laboratory values on the laboratory evaluations, medical history or surgery during the screening. Some of the laboratory values e.g. Complete blood count etc. that out of the normal range will be carefully considered by physician
排除标准
- •1. History or evidence of allergy or hypersensitivity to Venlafaxine or Desvenlafaxine succinate or any related drugs or any of the excipients of this product. 2. Subject with B.P. is Systolic B.P < 90, >=140 mm/Hg, Diastolic B.P < 60, >=90 mm/Hg, pulse rate > 100 beats per minute. 3. Serum bilirubin greater than 1.5 times the upper limit of reference range (ULRR).* 4. Serum creatinine greater than 1.5 times the upper limit of reference range (ULRR).* 5. Alanine amino transferase (ALT) or aspartate amino transferase (AST) greater than 2 times the upper limit of reference range (ULRR).* 6. Positive of hepatitis B, hepatitis C virus or HIV. 7. Have more than one abnormal EKG, which is considered as clinically significant. * 8. History or evidence of heart, renal, hepatic disease, pneumonia, lung fibrosis pulmonary obstructive disease, bronchial asthma, dyslipidemia, hypertension or glaucoma. 9. History or evidence of gastrointestinal disorder likely to influence drug absorption or previous GI surgery other than appendectomy. 10. Any major illness in the past 3 months or any significant ongoing chronic medical illness. 11. History of seizures or with conditions that lower the seizure threshold, e.g., Alzheimers dementia, severe head trauma. 12. History of psychiatric disorder, depression or suicidal attempt. 13. Hyponatremia* 14. History or presence of major active bleeding or abnormal bleeding due to hemorrhoids, epistaxis, gastrointestinal ulcer or other symptoms in past 1 month before the study drug administration and until the completion of the study. 15. History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) and cannot stop at least 2 days before the study drug administration and until the completion of each period of the study. 16. History of usually smoking (more than 10 cigarettes per day within past 1 year), if moderate smokers (less than 10 cigarettes per day) cannot stop at least 7 days before the study drug administration and until the completion of the study. 17. High caffeine consumption (more than 5 cups of coffee or tea per day) and cannot stop at least 2 days before the study drug administration and until the completion of each period of the study. 18. History of grapefruit, pomelo or grapefruit products consumption and cannot stop at least 7 days before the study drug administration and until the completion of the study. 19. History of St. Johns Wort products consumption and cannot stop at least 28 days before the study drug administration and until the completion of the study. 20. Positive drug abused test in urine (Benzodiazepines, Marijuana (THC), Methamphetamine, Cocaine and Opioids). 21. Receipt of any prescription drug therapy within 14 days or 5 half-lives (whichever longer) preceding the first dose of study medication or over-the-counter (OTC) drugs or herbal medicines/food supplement within 7 days or hormonal methods of contraception within 28 days (Depo-Provera must be discontinued at least 6 months) prior to receiving the first dose of study medication. 22. History of difficulty in accessibility of veins in left and right arm. 23. Blood donation (one unit or 450 mL) within the past 3 months before the study. 24. Participation in any clinical study within the past 3 months before the study. 25. Subjects who are unwilling or unable to comply with t
研究者
相似试验
已完成
1 期
A Bioequivalence study of single dose, two-way crossover design with two-period, two-treatment of Octreotide-SBS 100 mcg/mL subcutaneous injection relative to Sandostatin®Healthy VolunteersTCTR20180920004Siam Bioscience28
已完成
1 期
Comparative assessment of the absorption of a generic formulation of melatonin prolonged release tablet against the innovator melatonin prolonged release tablet conducted under fasting conditions and at steady state in healthy male and female volunteersBioequivalence study conducted in healthy volunteers comparing two formulations of melatonin with no health condition or problem studied.Although this study is being conducted in healthy volunteers who are not being treated for the condition to which the medicine is used, melatonin is a naturally occurring hormone produced by the pineal gland and is indicated as monotherapy for the short term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.Bioequivalence study conducted in healthy volunteers comparing two formulations of melatonin with no health condition or problem studied.Although this study is being conducted in healthy volunteers who are not being treated for the condition to which the medicine is used, melatonin is a naturally occurring hormone produced by the pineal gland and is indicated as monotherapy for the short term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.Other - Research that is not of generic health relevance and not applicable to specific health categories listed aboveACTRN12615000143527Zenith Technology Corp Ltd28
已完成
1 期
Comparative assessment of the absorption of a generic formulation of quetiapine prolonged release tablet against the innovator quetiapine tablet conducted under fasting conditions and at steady state in healthy male and female volunteersBioequivalence study conducted in healthy volunteers comparing two formulations of quetiapine with no health condition or problem studied. Although this study is being conducted in healthy volunteers who are not being treated for the condition to which the medicine is used, quetiapine belongs to a class of medicines called an atypical antipsychotic drug and is prescribed for the maintenance treatment of Bipolar and schizophrenia.Bioequivalence study conducted in healthy volunteers comparing two formulations of quetiapine with no health condition or problem studied.Although this study is being conducted in healthy volunteers who are not being treated for the condition to which the medicine is used, quetiapine belongs to a class of medicines called an atypical antipsychotic drug and is prescribed for the maintenance treatment of Bipolar and schizophrenia.Other - Research that is not of generic health relevance and not applicable to specific health categories listed aboveACTRN12613001134718Zenith Technology Corporation Limited36
已完成
1 期
Comparative assessment of the absorption of a generic formulation of 1,1-Dimethyl-2-Phenylethylamine 40 mg capsule against the innovator 1,1-Dimethyl-2-Phenylethylamine 40 mg capsule conducted under fasting condition and at steady state in healthy male and female volunteers.ACTRN12618000563268Zenith Technology Corporation Limited24
已完成
1 期
Comparative assessment of the absorption of a generic formulation of ibuprofen sustained release tablet against the innovator ibuprofen tablet conducted under fasting conditions and at steady state in healthy male and female volunteersACTRN12615000078550Zenith Technology Corporation Limited24